Mizzy-Inc. – Trademark Portfolio

Entity Type: 03

Mizzy-Inc. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 11 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include FLECK'S and HEATLESS. The owner is based in NEW YORK, NY.

1 UNION SQUARE

NEW YORK, NY

19 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Mizzy-Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (11 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (7 filings)

Surgical, medical, dental and veterinary apparatus and instruments

7
Machinery (1 filing)

Machines and machine tools; motors and engines; machine coupling and transmission components

Frequently Asked Questions

How many trademarks does Mizzy-Inc. have?

Mizzy-Inc. has 19 U.S. trademarks filed with the USPTO. Of these, 2 registered, 17 cancelled.

What trademark classes does Mizzy-Inc. file in?

Mizzy-Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 7 (Machinery). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Mizzy-Inc.'s most well-known trademarks?

Mizzy-Inc.'s registered trademark portfolio includes well-known marks such as FLECK'S and HEATLESS. These are among 2 currently registered trademarks in the portfolio.

What is Mizzy-Inc.'s trademark registration success rate?

Mizzy-Inc. has a 11% trademark registration rate, with 2 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.